In:
Bioanalysis, Future Science Ltd, Vol. 6, No. 15 ( 2014-08), p. 2071-2082
Abstract:
Background: apixaban (BMS-562247) (Eliquis ® ) is a novel, orally active, selective, direct, reversible inhibitor of the coagulation factor Xa (FXa). A sensitive and reliable method was developed and validated for the measurement of apixaban (BMS-562247) and its major circulating metabolite (BMS-730823) in human citrated plasma for use in clinical testing. Methodology/results: A 0.100 ml portion of citrated plasma sample was extracted and analyzed by LC–MS/MS. Run times were approximately 3 min. The lower limit of quantification (LLOQ) was 1.00 ng/ml for BMS-562247 and 5.00 ng/ml for BMS-730823. Intra- and inter-assay precision values for replicate QC control samples were within ≤5.36% for both analytes (≤7.52% at the LLOQ). The accuracy for both analytes was within ±9.00%. Conclusion: The method was demonstrated to be sensitive, selective and robust, and was successfully used to support clinical studies.
Type of Medium:
Online Resource
ISSN:
1757-6180
,
1757-6199
Language:
English
Publisher:
Future Science Ltd
Publication Date:
2014
SSG:
15,3
Permalink